1 unchanged sentence
(c) Trading Plans
−Removed: During the quarter ended March 31, 2026, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
+Added: During the quarter ended June 30, 2026, the following directors and officers (as defined in Exchange Act Rule 16a-1(f)) adopted certain trading plans intended to satisfy Rule 10b5-1(c):
Name Title Adoption or Termination Date Plan End Date Shares Vesting and Subject to Sell-To-Cover (1)
Other Shares Being Sold (Subject to Certain Conditions)
−Removed: Victoria Vakiener Board Member 01/12/2026 12/31/2026 4,300
−Removed: Adeoye Olukotun Board Member 01/14/2026 12/31/2026 7,819
−Removed: Hongbo Lu Board Member 01/14/2026 12/31/2026 7,449
−Removed: William Waddill Board Member 02/25/2026 12/31/2026 3,910
−Removed: Daniel Apel Chief Financial Officer 03/29/2026 04/27/2027 43,750
+Added: Patrick O’Brien Chief Operating Officer 04/09/2026 01/08/2027 Up to 30,000 Shares
+Added: Patrick O’Brien Chief Operating Officer 04/09/2026 01/08/2027 81,250
+Added: Mauro Ferrari Board Member 04/14/2026 12/22/2026 3,128
(1) This column indicates the total number of shares vesting, but the 10b5-1 Plan provides for the sale of only those shares necessary to satisfy payment of applicable withholding taxes.
4 unchanged sentences
Second Amended and Restated Bylaws of Arrowhead Pharmaceuticals, Inc., as amended January 24, 2023 (incorporated by reference from Exhibit 3.3 of the Company's Form 10-Q filed on February 5, 2026)
−Removed: Form of Pre-Funded Warrant (incorporated by reference from Exhibit 4.1 of the Company’s Form 8-K filed on January 9, 2026)
−Removed: Indenture, dated as of January 12, 2026, between Arrowhead Pharmaceuticals, Inc.
−Removed: Bank Trust Company, National Association, as trustee (incorporated by reference from Exhibit 4.1 of the Company’s Form 8-K filed on January 12, 2026)
−Removed: First Supplemental Indenture, dated as of January 12, 2026, between Arrowhead Pharmaceuticals, Inc.
−Removed: Bank Trust Company, National Association, as trustee (incorporated by reference from Exhibit 4.2 of the Company’s Form 8-K filed on January 12, 2026)
−Removed: Form of certificate representing the 0.00% Convertible Senior Notes due 2032 (incorporated by reference from Exhibit 4.3 of the Company’s Form 8-K filed on January 12, 2026)
10.1*# Arrowhead Pharmaceuticals, Inc.
2 unchanged sentences
Amended and Restated Inducement Plan
+Added: License Agreement by and between Arrowhead Pharmaceuticals, Inc.
+Added: and Madrigal Pharmaceuticals, Inc., dated May 4, 2026
+Added: 10.4* Third Amendment to Office Lease by and between Arrowhead Pharmaceuticals, Inc.
+Added: and 177 Colorado Owner LLC., dated April 2 7 , 2026
31.1* Certification of Chief Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
17 unchanged sentences
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Quarterly Report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
+Added: August 4, 2026
ARROWHEAD PHARMACEUTICALS, INC.
3 unchanged sentences
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.